US equities |
AAPL $338.32 ▲+0.00% PLTR $178.34 ▲+0.00% MU $833.59 ▲+0.00% SNDK $1,075.08 ▲+0.00% NVDA $202.06 ▲+0.00% INTC $59.97 ▲+0.00% ORCL $119.22 ▲+0.00% GOOGL $278.99 ▲+0.00%
FinancialContent

Bioventus Inc. - Class A Common Stock (NQ:BVS)

13.15 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bioventus Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Bioventus (BVS) Q3 2026 Earnings Call Transcript ↗
Pain treatments drove 3% revenue growth as management targets $100M+ for nerve stimulation. 
Via The Motley Fool
Topics Earnings
News headline image
Bioventus Q3 Earnings Call Highlights ↗
Bioventus (NASDAQ:BVS) reported third-quarter revenue growth of 3% as strength in its Pain Treatments business, Ultrasonics operation and international markets was partly offset by softness in bone... 
Via MarketBeat
Topics Earnings
Bioventus (NASDAQ:BVS) Falls After Q3 Revenue Miss and Below-Consensus Sales Guidance Despite EPS Beat ↗
Via Chartmill
News headline image
Bioventus Reports Third Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus (NASDAQ:BVS) Falls After Q2 Revenue Miss, Launches Strategic Review ↗
Via Chartmill
Bioventus Inc (NASDAQ:BVS) Smashes Q1 Estimates and Lifts Guidance, Shares Rally ↗
Via Chartmill
Bioventus Inc (NASDAQ:BVS) Reports Q4 Earnings Beat and Strong 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus (BVS) Q2 2026 Earnings Call Transcript ↗
Pain Treatments surged 11.5% as management explores strategic alternatives. 
Via The Motley Fool
Topics Earnings
News headline image
Bioventus Q2 Earnings Call Highlights ↗
Bioventus (NASDAQ:BVS) reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt... 
Via MarketBeat
Topics Earnings
News headline image
Bioventus Reports Second Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
From Bioventus, Inc.
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls ↗
Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering... 
Via MarketBeat
Topics Initial Public Offering
News headline image
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus (BVS) Q1 2026 Earnings Transcript ↗
Bioventus (BVS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics World Trade
News headline image
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Bioventus (BVS) Q4 2025 Earnings Call Transcript ↗
Bioventus (BVS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Bioventus Inc (NASDAQ:BVS) Reports Q3 2025 Earnings Beat and Strong Profitability Growth ↗
Bioventus (BVS) reported strong Q3 2025 earnings, beating EPS estimates with a 200% surge. While revenue slightly missed, organic growth was up 8.2%. 
Via Chartmill
Topics Earnings
News headline image
Bioventus Reports Third Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
From Bioventus, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >